Send to

Choose Destination
Oncoimmunology. 2014 Jun 25;3:e29289. eCollection 2014.

Immunological targeting of cytomegalovirus for glioblastoma therapy.

Author information

Department of Surgery; Duke University Medical Center; Duke Cancer Institute; Durham, NC USA.
Preston A. Wells, Jr. Center for Brain Tumor Therapy; Department of Neurosurgery; University of Florida; Gainesville, FL USA.


Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.


RNA-transfected dendritic cells; cytomegalovirus; glioblastoma; immunotherapy

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center